Comparison of Survival after Sublobar Resections and Ablative Therapies for Stage I Non−Small Cell Lung Cancer

This experience suggests comparable survival after sublobar resections and ablative therapies at 3 years. Ablative therapies appear to be a reasonable alternative in high-risk patients not fit for surgery. However, larger randomized studies with longer follow-up are needed to make recommendations for therapy.